GSK plcGSK plcGSK plc

GSK plc

No trades
See on Supercharts

Key facts today


GSK plc faces a class action lawsuit over alleged misrepresentation of Zantac's withdrawal and NDMA risks, affecting investors who bought ADRs from February 2020 to August 2022.
GSK's asthma drug Nucala has been accepted for review by the European Medicines Agency for COPD treatment. Phase 3 trial results showed a significant reduction in exacerbations.
On March 24, 2025, GSK plc bought 13,449,987 shares in its buyback program, raising total treasury shares to 182,520,290, with 4,132,694,556 shares issued excluding treasury.
Analyze the impactAnalyze the impact
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪79.29 B‬USD
1.60USD
‪3.29 B‬USD
‪40.09 B‬USD
‪2.04 B‬
Beta (1Y)
0.17

About GSK PLC ORD GBP0.3125


CEO
Emma N. Walmsley
Website
Headquarters
London
FIGI
BBG000BLB481
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
XS217060907
GLAXOSM.CAP. MTN 20/35MTN
Yield to maturity
6.39%
Maturity date
May 12, 2035
17RI
GLAXOSMITHKLINE CAPITAL PLC 4.25% GTD SNR EMTN 18/12/45
Yield to maturity
6.06%
Maturity date
Dec 18, 2045
83GI
GLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 10/04/2042
Yield to maturity
5.96%
Maturity date
Apr 10, 2042
GSK3981911
GlaxoSmithKline Capital, Inc. 4.2% 18-MAR-2043
Yield to maturity
5.68%
Maturity date
Mar 18, 2043
71ZC
GLAXOSMITHKLINE CAPITAL PLC 6.375% GTD SNR EMTN 09/03/39
Yield to maturity
5.55%
Maturity date
Mar 9, 2039
GSK4632357
GlaxoSmithKline Capital, Inc. 3.625% 15-MAY-2025
Yield to maturity
5.54%
Maturity date
May 15, 2025
GSK.GJ
GlaxoSmithKline Capital, Inc. 6.375% 15-MAY-2038
Yield to maturity
5.12%
Maturity date
May 15, 2038
GSK6023693
GlaxoSmithKline Capital, Inc. 4.875% 15-APR-2035
Yield to maturity
5.08%
Maturity date
Apr 15, 2035
AG99
GLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 19/12/2033
Yield to maturity
4.94%
Maturity date
Dec 19, 2033
GSK6023692
GlaxoSmithKline Capital Plc FRN 12-MAR-2027
Yield to maturity
4.69%
Maturity date
Mar 12, 2027
XS217060184
GLAXOSM.CAP. MTN 20/28MTN
Yield to maturity
4.66%
Maturity date
Oct 12, 2028

See all GSK bonds 

Curated watchlists where GSK is featured.

Check out other big names from the same industry as GSK.